FDA Approves Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia | Targeted Oncology

FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation. News release. US FDA. November 13, 2025. Accessed …